BACKGROUND Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance.
(UroToday.com) VERU-111 is an oral, next-generation, first-in-class selective small molecule that targets and binds to the alpha and beta-tubulin subunits of microtubules in cells. Microtubules are essential components for cell division and for shuttling critical growth receptors into the nucleus, where they stimulate cell proliferation. Unlike taxane chemotherapy, which only binds the beta subunit of […]
(UroToday.com) Once patients with advanced urothelial cancer progress through platinum chemotherapy and anti-PD-1 axis immunotherapy, treatment options are limited. Enfortumab vedotin is an antibody-drug conjugate directed against the Nectin-4 protein, which is expressed at high levels on the surface of many types of cancers including urothelial cancers, and delivers the microtubule-disrupting cytotoxic agent monomethyl auristatin E […]
(UroToday.com) At the European Society of Medical Oncology – 2020 Virtual Congress (ESMO), Dr. David Margel presented data regarding the first round of screening from an imaging-based prostate cancer screening program among BRCA mutation carriers. There are clear guidelines for screening female BRCA-carriers for breast and ovarian cancer, however male BRCA-carrier screening for prostate cancer has […]
(UroToday.com) The KEYNOTE-427 trial was a phase II international trial of the anti-PD-1 monoclonal antibody pembrolizumab as monotherapy in metastatic renal cell carcinoma. This agent showed promising activity as monotherapy in both clear cell and non-clear cell histologies, with some association between PD-L1 positivity as measured by Combined Positivity Score (CPS ≥ 1. The CPS score […]
San Francisco, CA (UroToday.com) — Prostate cancer is the most common cancer in American men except for skin cancers, according to the American Cancer Society. However, innovations in diagnostics and treatment have made prostate cancer a very treatable disease, with a 98% five-year survival rate.
(UroToday.com) The PD-1 inhibitor pembrolizumab has shown activity in a study of heavily pretreated patients with PD-L1-positive advanced prostate cancer and in a study of PD-L1-positive or PD-L1-negative patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who received more than one next-generation hormonal agent.1 Pembrolizumab plus docetaxel and prednisone (cohort B) has shown […]
(UroToday.com) Pembrolizumab has shown activity in a study of heavily pretreated patients with PD-L1-positive advanced prostate cancer and in a study of PD-L1-positive or PD-L1-negative patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who received more than one next-generation hormonal agent.1 Olaparib is a poly adenosine diphosphate ribose polymerase (PARP) inhibitor that has […]
(UroToday.com) Pembrolizumab monotherapy has demonstrated durable activity in PD-L1-positive metastatic castration-resistant prostate cancer.1, 2 A single-institution phase 2 study (n=28) of pembrolizumab plus enzalutamide in patients whose disease progressed after enzalutamide showed that the treatment combination demonstrated promising efficacy, suggesting that pembrolizumab plus enzalutamide may be a potential treatment option.3 KEYNOTE-199, is an open-label, global, multicohort, […]
(UroToday.com) The neutrophil-to-lymphocyte ratio (NLR) could be established as an important prognostic marker for the outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with chemotherapy, steroids, and novel androgen receptor directed therapies. Thus far, the value of the NLR as a biomarker in the context of therapeutic radionuclides has never been explored. At the European […]
